Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults
Tralokinumab is an effective and safe treatment for adult patients with moderate-to-severe AD. It may be used alone or in combination with TCS. This biologic can be considered first-line treatment after failure of or intolerance to topical therapies.
Antibiotic Resistance in Dermatology Part 1: Mechanisms of Resistance
Awareness of the molecular mechanisms of antibiotic resistance among bacteria is necessary to understand the etiology of antibiotic resistance in dermatology at the most basic level.
Update on Drugs & Devices: January – February 2023
Update covering: Deucravacitinib tablets (Sotyktu™), mRNA vaccine + pembrolizumab IV combination therapy (mRNA-4157/V940 + Keytruda®), Adalimumab-aacf SC injection (Idacio®), Dupilumab for SC injection (Dupixent®), and Spesolimab IV injection (Spevigo®).
Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis
Moderate to severe chronic plaque psoriasis may be difficult to control using current therapies, which has led to development of a novel class of therapy, selective tyrosine kinase 2 (TYK2) inhibitors, to address this unmet need.
Acne Scars: An Update on Management
Acne scars are a frequent complication that results from damage to the skin during the healing process of lesions, with studies indicating that 50% of those suffering from acne may develop scars.
Update on Drugs & Devices: November – December 2022
Update covering: Deucravacitinib tablets (Sotyktu™), DaxibotulinumtoxinA-lanm IM injection (Daxxify™), Dupilumab for SC injection (Dupixent®), Spesolimab-sbzo IV injection (Spevigo®) and Selumetinib capsules (Koselugo™).
Extracorporeal Photopheresis and Its Use in Clinical Dermatology in Canada
Results from multiple studies have shown promising response rates, and extracorporeal photopheresis has an overall excellent safety profile with very few adverse events reported.
Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches
Toxic epidermal necrolysis (TEN) is an immune-mediated, severe cutaneous adverse drug reaction characterized by epidermal detachment affecting greater than 30% body surface area.
Update on Drugs & Devices: September – October 2022
Update covering: Roflumilast cream 0.3% (Zoryve™), Ruxolitinib cream 1.5% (Opzelura™), HA-based dermal filler (Juvéderm® Volux™ XC), Abrocitinib tablets (Cinbinqo®), LetibotulinumtoxinA for injection (Letybo®), Berotralstat capsules (Orladeyo®), Mogamulizumab IV infusion (Poteligeo®), and Avacopan capsules (Tavneos®).
Tazarotene Lotion 0.045% for the Treatment of Acne
Tazarotene 0.045% lotion is a novel formulation which utilizes polymeric emulsion technology to improve tolerability and epidermal penetration. Despite the lower concentration of tazarotene in the lotion formulation, which likely also contributes to improved tolerability, tazarotene 0.045% lotion is at least as effective as tazarotene 0.1% cream.
Tirbanibulin for the Treatment of Actinic Keratosis: A Review
Tirbanibulin effectively and completely cleared AK lesions with a 5-day application period while demonstrating a favorable safety profile, mild AEs, improved tolerability, and long-term results, making it a promising field therapy for AKs.
Update on Drugs & Devices: July-August 2022
Update covering: Benzoyl peroxide 5% cream, Isotretinoin ointment, Tapinarof 1% cream, Baricitinib tablets, and Dupilumab for SC injection.
Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses
A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults.
Sarecycline: A Narrow-Spectrum Antibiotic
Sarecycline is a novel antibiotic that has shown significant promise in acne treatment due to its narrow-spectrum activity and weight-based dosing.
Update on Drugs & Devices: May-June 2022
This update covers Nivolumab + Relatlimab-rmbw for IV use - Opdualag™ (Bristol-Myers Squibb), Sirolimus topical gel 0.2% - Hyftor™ (Nobelpharma America), Oral epinephrine - AQST-109 (Aquestive Therapeutics), and Bimekizumab for SC use - Bimzelx® (UCB Canada Inc.).
Plerixafor on a WHIM – Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
Emerging molecular experimental and clinical data suggests that CXCR4 may play an important role in other skin and systemic diseases including mycosis fungoides/Sézary syndrome, neurofibromatosis type 1 tumors, allergic reactions, Waldenström macroglobulinemia, melanoma, non-melanoma skin cancers and other solid tumors.
Transition of Topical Therapy Formulation in Psoriasis: Insights from a Canadian Practice Reflective
The benefits of transitioning from Cal/BD ointment or gel to aerosol foam formulation in this Canadian patient population were similar to those reported in clinical studies and were seen consistently among patients with a range of treatment priorities and with differing history of psoriasis severity and treatment history.
Update on Drugs & Devices: March-April 2022
This update covers Adalimumab biosimilar - Yuflyma™ (Celltrion Healthcare), Adalimumab biosimilar - Simlandi™ (Alvotech/JAMP Pharma), Abrocitinib tablet - Cibinqo® (Pfizer), Upadacitinib tablet - Rinvoq® (AbbVie), Risankizumab-rzaa SC injection - Skyrizi® (AbbVie), and HA-based dermal filler - Juvéderm® Volbella® XC (AbbVie/ Allergan Aesthetics).
Topical Clascoterone for Acne Vulgaris
Clascoterone 1% cream represents a novel and promising therapeutic agent in the management of acne vulgaris for individuals ≥12 years of age. Notably, this topical agent was not observed to have significant systemic effects seen with systemic anti-androgenic agents.
Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications
Currently, JAK inhibitors are only FDA approved for dermatologic, rheumatologic, and hematologic conditions. Recent studies show the utility of JAK inhibitors in treating atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, and alopecia areata.
Update on Drugs & Devices: January-February 2022
Drug update covering: Adalimumab-adbm for SC use - Cyltezo®, Tralokinumab for SC use - Adtralza® (in Canada), Tralokinumab-ldrm for SC use - Adbry™ (in US), Melanoma vaccine for IV use - BNT111, Adalimumab-aqvh for SC use - Yusimry™, and more...
2021 Index for Skin Therapy Letter Volume 26 – Dermatology Edition
This index covers all articles published in Skin Therapy Letter Dermatology Edition articles in 2021. Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.
Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis
A novel fixed combination lotion containing the super-potent corticosteroid halobetasol propionate 0.01% and retinoid tazarotene 0.045% (Duobrii™) has recently been introduced and indicated for the treatment of moderate to severe plaque psoriasis in adults.
Psoriasis Education Tool for Patient-Physician Decision-Making About Biologics: A Pilot Study
Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment.
Update on Drugs & Devices: November-December 2021
The update covers Difelikefalin for IV use - Korsuva™ (Vifor Pharma, Cara Therapeutics), Topical MEK inhibitor - NFX-179 (NFlextion Therapeutics), Maralixibat oral solution - Livmarli™ (Mirum Pharmaceuticals), Ruxolitinib cream 1.5% - Opzelura™ (Incyte), Ruxolitinib tablets - Jakafi® (Incyte), and Avacopan capsules - Tavneos™ (ChemoCentryx).
Labeling Laws for Personal Care Products: Potential Pitfalls for The Consumer
Consumers of personal care products must be made aware of the potential pitfalls that arise from current labeling practices and regulations. For example, terms such as “hypoallergenic“, “sensitive skin“, and ...
Hair Removal Practices: A Literature Review
This article is a general overview of hair removal practices, which have evolved from utilizing waxes and blades, to advanced lasers and electrolysis, with further advancements still being studied
Update on Drugs & Devices: September – October 2021
The update covers: Tazarotene lotion, 0.045% - Arazlo™ (Bausch Health), Anifrolumab-fnia IV use - Saphnelo™ (AstraZeneca), Immune globulin intravenous (human) 10% - Octagam® 10% (Octapharma), Odevixibat capsule - Bylvay™ (Albireo Pharma) and other treatments
Rosacea: An Update in Diagnosis, Classification and Management
This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.
Moisturizers and Cleansers in the Management of Skin Conditions Caused by Personal Protective Equipment and Frequent Handwashing
Routine moisturization with non-irritating, pH-adjusted, ceramide-based products and gentle cleansing with a pH-adjusted cleanser can treat the unique dermatological challenges posed by COVID-19.
Update on Drugs & Devices: July – August 2021
The update covers: Secukinumab for SC use - Cosentyx® (Novartis), Brincidofovir tablets and
oral suspension - Tembexa® (Chimerix), Plasminogen, humantvmh - Ryplazim® (Liminal BioSciences), Halobetasol propionate
lotion 0.01% w/w - Bryhali™ (Bausch Health), and Nomacopan for SC use (Akari Therapeutics).
Bimekizumab for Moderate-to-Severe Plaque Psoriasis
Bimekizumab is a novel treatment for moderate-to-severe plaque psoriasis that has shown promising efficacy and safety in clinical trials. By simultaneously targeting two components of the IL-17 pathway, IL-17A and IL-17F, the biologic can downregulate proinflammatory signaling and rapidly improve patients’ skin.
Prurigo Nodularis: Review and Emerging Treatments
Novel therapeutics are currently being explored for the treatment of Prurigo Nodularis. Nemolizumab and dupilumab both demonstrate promise in inhibiting specific central nervous system pathways responsible for transmission of the pruritic sensation.
Update on Drugs & Devices: May-June 2021
The update covers: Axatilimab IV injection - SNDX-6352 (Syndax Pharmaceuticals), Binimetinib tablets + encorafenib capsules - Mektovi® + Braftovi® (Pfizer Canada), Encapsulated cell therapy for Fabry disease - SIG-007 (Sigilon Therapeutics) and Oritavancin IV injection - Kimyrsa™ (Melinta Therapeutics).
Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy
Certolizumab Pegol appears to offer a safe and effective psoriasis treatment for patients who are considering pregnancy, pregnant, or lactating based on its pharmacokinetics and available safety data.
Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions
HPV vaccines (Gardasil and Cervarix) may indeed have a therapeutic role in patients who suffer from dermatologic conditions that are associated with various strains of HPV.
Skin Treatments Introduced in 2020
This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.
Update on Drugs & Devices: March-April 2021
The update covers: Cemiplimab-rwlc for IV injection - Libtayo® (Regeneron/Sanofi), HA-based dermal filler - Restylane® Defyne™ (Galderma), Tirbanibulin ointment 1% - Klisyri® (Almirall/Athenex), Anakinra for SC use - Kineret® (Swedish Orphan Biovitrum Sobi™), Immune modulatory vaccines for melanoma - IO102 and IO103 (IO Biotech).
Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis
Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.
Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis
Early clinical trial data indicate the increasing effectiveness and safety of efinaconazole 10% solution use beyond 12 months; application for up to 24 months appears to remain safe even for elderly patients.